---
document_datetime: 2025-12-02 05:14:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/camcevi.html
document_name: camcevi.html
version: success
processing_time: 0.0748928
conversion_datetime: 2025-12-24 07:53:26.731934
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Camcevi

[RSS](/en/individual-human-medicine.xml/67566)

##### Authorised

This medicine is authorised for use in the European Union

leuprorelin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Camcevi](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Camcevi is a medicine used in adult men for the treatment of advanced prostate cancer that is 'hormone-dependent', meaning that it responds to treatments that lower the level of the hormone testosterone. Camcevi is also used in combination with radiotherapy to treat locally advanced hormone-dependent prostate cancer and high-risk localised prostate cancer (this means that the cancer is likely to spread beyond the prostate gland to nearby tissues and become 'locally advanced').

Camcevi is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substance but has a different formulation. The reference medicine for Camcevi is Eligard. Camcevi is available as a ready-to-use medicine in contrast with Eligard, which requires pre-mixing before it can be given to the patient.

The active substance in Camcevi is leuprorelin.

Expand section

Collapse section

## How is Camcevi used?

Camcevi is available as prolonged-release suspension for injection in a pre-filled syringe. Prolonged-release means that the active substance is released slowly over a six-month period after being injected. Injections are given under the skin.

Camcevi can only be obtained with a prescription. Treatment should be given by a healthcare professional experienced in using the medicine and under the supervision of a doctor experienced in monitoring the treatment of prostate cancer.

For more information about using Camcevi, see the package leaflet or contact your doctor or pharmacist.

## How does Camcevi work?

Testosterone can make prostate cancer cells grow. When present continuously, the active substance in Camcevi, leuprorelin, reduces the amount of testosterone in the body by blocking the effects of a natural hormone called gonadotrophin-releasing hormone (GnRH). GnRH is the first step in a system responsible for testosterone production. By blocking GnRH and thus reducing the level of testosterone, Camcevi slows down the growth of the cancer cells. When injected, Camcevi forms a gel under the skin that releases the active substance slowly over six months.

## What benefits of Camcevi have been shown in studies?

The company provided data from the published literature on the benefits and risks of leuprorelin in the approved use.

As for every medicine, the company provided studies on the quality of Camcevi. They also presented results from a study which showed that treatment with Camcevi lowered the amount of testosterone to levels comparable to those previously reported for the reference medicine. This study included 137 men with hormone-dependent prostate cancer who were given two doses of Camcevi 24 weeks apart. Four weeks after the first injection, 98.5% (135 out of 137) of patients experienced a decrease in testosterone to levels similar to those seen in men after chemical or surgical castration. Testosterone levels remained below castration levels during the 48-week treatment period in 97% (133 out of 137) patients.

## What are the risks associated with Camcevi?

The most common side effect with Camcevi (which may affect more than 1 in 2 people) is the occurrence of mild or moderate hot flushes. Other side effects include nausea, malaise (feeling generally unwell), tiredness and irritation at the injection site.

For the full list of side effects of Camcevi, see the package leaflet.

Camcevi must not be used in patients whose testicles have been surgically removed, as sole treatment in patients with spinal cord compression or those whose cancer has metastasised (spread) to the spine. Camcevi must also not be used in patients allergic to the active substance, to any other ingredients or to other GnRH agonists (substances that attach to a GnRH receptor (target) and trigger an effect).

## Why is Camcevi authorised in the EU?

The European Medicines Agency concluded that in accordance with EU requirements, Camcevi has been shown to be comparable to Eligard. In addition, Camcevi's ready-to-use formulation means it is easier to use. Therefore, the Agency decided that Camcevi's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Camcevi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Camcevi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Camcevi are continuously monitored. Side effects reported with Camcevi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Camcevi

Camcevi received a marketing authorisation valid throughout the EU on 24 May 2022.

Camcevi : EPAR - Medicine overview

Reference Number: EMEA/H/C/005034

English (EN) (137.22 KB - PDF)

**First published:** 20/06/2022

[View](/en/documents/overview/camcevi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-613)

български (BG) (141.03 KB - PDF)

**First published:**

20/06/2022

[View](/bg/documents/overview/camcevi-epar-medicine-overview_bg.pdf)

español (ES) (117.52 KB - PDF)

**First published:**

20/06/2022

[View](/es/documents/overview/camcevi-epar-medicine-overview_es.pdf)

čeština (CS) (138.61 KB - PDF)

**First published:**

20/06/2022

[View](/cs/documents/overview/camcevi-epar-medicine-overview_cs.pdf)

dansk (DA) (115.08 KB - PDF)

**First published:**

20/06/2022

[View](/da/documents/overview/camcevi-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.61 KB - PDF)

**First published:**

20/06/2022

[View](/de/documents/overview/camcevi-epar-medicine-overview_de.pdf)

eesti keel (ET) (104.49 KB - PDF)

**First published:**

20/06/2022

[View](/et/documents/overview/camcevi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (138.98 KB - PDF)

**First published:**

20/06/2022

[View](/el/documents/overview/camcevi-epar-medicine-overview_el.pdf)

français (FR) (118.09 KB - PDF)

**First published:**

20/06/2022

[View](/fr/documents/overview/camcevi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (137.61 KB - PDF)

**First published:**

20/06/2022

[View](/hr/documents/overview/camcevi-epar-medicine-overview_hr.pdf)

italiano (IT) (115.86 KB - PDF)

**First published:**

20/06/2022

[View](/it/documents/overview/camcevi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (154.76 KB - PDF)

**First published:**

20/06/2022

[View](/lv/documents/overview/camcevi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138.91 KB - PDF)

**First published:**

20/06/2022

[View](/lt/documents/overview/camcevi-epar-medicine-overview_lt.pdf)

magyar (HU) (138.7 KB - PDF)

**First published:**

20/06/2022

[View](/hu/documents/overview/camcevi-epar-medicine-overview_hu.pdf)

Malti (MT) (140.75 KB - PDF)

**First published:**

20/06/2022

[View](/mt/documents/overview/camcevi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (116.42 KB - PDF)

**First published:**

20/06/2022

[View](/nl/documents/overview/camcevi-epar-medicine-overview_nl.pdf)

polski (PL) (140.79 KB - PDF)

**First published:**

20/06/2022

[View](/pl/documents/overview/camcevi-epar-medicine-overview_pl.pdf)

português (PT) (118.17 KB - PDF)

**First published:**

20/06/2022

[View](/pt/documents/overview/camcevi-epar-medicine-overview_pt.pdf)

română (RO) (135.41 KB - PDF)

**First published:**

20/06/2022

[View](/ro/documents/overview/camcevi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (138.9 KB - PDF)

**First published:**

20/06/2022

[View](/sk/documents/overview/camcevi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (135.09 KB - PDF)

**First published:**

20/06/2022

[View](/sl/documents/overview/camcevi-epar-medicine-overview_sl.pdf)

Suomi (FI) (113.1 KB - PDF)

**First published:**

20/06/2022

[View](/fi/documents/overview/camcevi-epar-medicine-overview_fi.pdf)

svenska (SV) (115.55 KB - PDF)

**First published:**

20/06/2022

[View](/sv/documents/overview/camcevi-epar-medicine-overview_sv.pdf)

Camcevi : EPAR - Risk management plan summary

English (EN) (113.05 KB - PDF)

**First published:** 20/06/2022

[View](/en/documents/rmp-summary/camcevi-epar-risk-management-plan-summary_en.pdf)

## Product information

Camcevi : EPAR - Product Information

English (EN) (411.11 KB - PDF)

**First published:** 20/06/2022

**Last updated:** 03/04/2025

[View](/en/documents/product-information/camcevi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-201)

български (BG) (447.38 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/bg/documents/product-information/camcevi-epar-product-information_bg.pdf)

español (ES) (410.9 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/es/documents/product-information/camcevi-epar-product-information_es.pdf)

čeština (CS) (395.6 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/cs/documents/product-information/camcevi-epar-product-information_cs.pdf)

dansk (DA) (373.2 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/da/documents/product-information/camcevi-epar-product-information_da.pdf)

Deutsch (DE) (430.67 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/de/documents/product-information/camcevi-epar-product-information_de.pdf)

eesti keel (ET) (399.96 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/et/documents/product-information/camcevi-epar-product-information_et.pdf)

ελληνικά (EL) (451.64 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/el/documents/product-information/camcevi-epar-product-information_el.pdf)

français (FR) (429.68 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/fr/documents/product-information/camcevi-epar-product-information_fr.pdf)

hrvatski (HR) (439.52 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/hr/documents/product-information/camcevi-epar-product-information_hr.pdf)

íslenska (IS) (347.66 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/is/documents/product-information/camcevi-epar-product-information_is.pdf)

italiano (IT) (434.57 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/it/documents/product-information/camcevi-epar-product-information_it.pdf)

latviešu valoda (LV) (430.98 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/lv/documents/product-information/camcevi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (411.37 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/lt/documents/product-information/camcevi-epar-product-information_lt.pdf)

magyar (HU) (466.01 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/hu/documents/product-information/camcevi-epar-product-information_hu.pdf)

Malti (MT) (428.81 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/mt/documents/product-information/camcevi-epar-product-information_mt.pdf)

Nederlands (NL) (387.39 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/nl/documents/product-information/camcevi-epar-product-information_nl.pdf)

norsk (NO) (385.88 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/no/documents/product-information/camcevi-epar-product-information_no.pdf)

polski (PL) (463.52 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/pl/documents/product-information/camcevi-epar-product-information_pl.pdf)

português (PT) (410.9 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/pt/documents/product-information/camcevi-epar-product-information_pt.pdf)

română (RO) (420.89 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/ro/documents/product-information/camcevi-epar-product-information_ro.pdf)

slovenčina (SK) (393.93 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/sk/documents/product-information/camcevi-epar-product-information_sk.pdf)

slovenščina (SL) (435.08 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/sl/documents/product-information/camcevi-epar-product-information_sl.pdf)

Suomi (FI) (376.38 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/fi/documents/product-information/camcevi-epar-product-information_fi.pdf)

svenska (SV) (365 KB - PDF)

**First published:**

20/06/2022

**Last updated:**

03/04/2025

[View](/sv/documents/product-information/camcevi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000261705 03/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Camcevi : EPAR - All Authorised Presentations

English (EN) (43.38 KB - PDF)

**First published:** 20/06/2022

[View](/en/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-163)

български (BG) (51.76 KB - PDF)

**First published:**

20/06/2022

[View](/bg/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.14 KB - PDF)

**First published:**

20/06/2022

[View](/es/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (58.39 KB - PDF)

**First published:**

20/06/2022

[View](/cs/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.19 KB - PDF)

**First published:**

20/06/2022

[View](/da/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (44.97 KB - PDF)

**First published:**

20/06/2022

[View](/de/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (42.81 KB - PDF)

**First published:**

20/06/2022

[View](/et/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (57.76 KB - PDF)

**First published:**

20/06/2022

[View](/el/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_el.pdf)

français (FR) (43.17 KB - PDF)

**First published:**

20/06/2022

[View](/fr/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (60.32 KB - PDF)

**First published:**

20/06/2022

[View](/hr/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (43.73 KB - PDF)

**First published:**

20/06/2022

[View](/is/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (42.06 KB - PDF)

**First published:**

20/06/2022

[View](/it/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (57.55 KB - PDF)

**First published:**

20/06/2022

[View](/lv/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (60.17 KB - PDF)

**First published:**

20/06/2022

[View](/lt/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (60.92 KB - PDF)

**First published:**

20/06/2022

[View](/hu/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (61.95 KB - PDF)

**First published:**

20/06/2022

[View](/mt/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (43.02 KB - PDF)

**First published:**

20/06/2022

[View](/nl/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (44.68 KB - PDF)

**First published:**

20/06/2022

[View](/no/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_no.pdf)

polski (PL) (64.1 KB - PDF)

**First published:**

20/06/2022

[View](/pl/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_pl.pdf)

português (PT) (43.98 KB - PDF)

**First published:**

20/06/2022

[View](/pt/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_pt.pdf)

română (RO) (60.56 KB - PDF)

**First published:**

20/06/2022

[View](/ro/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (58.97 KB - PDF)

**First published:**

20/06/2022

[View](/sk/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (61.1 KB - PDF)

**First published:**

20/06/2022

[View](/sl/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (40.08 KB - PDF)

**First published:**

20/06/2022

[View](/fi/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (43.02 KB - PDF)

**First published:**

20/06/2022

[View](/sv/documents/all-authorised-presentations/camcevi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Camcevi Active substance leuprorelin mesilate International non-proprietary name (INN) or common name leuprorelin Therapeutic area (MeSH) Prostatic Neoplasms

### Pharmacotherapeutic group

Endocrine therapy

### Therapeutic indication

Camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

## Authorisation details

EMA product number EMEA/H/C/005034 Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 24/03/2022 Marketing authorisation issued 24/05/2022 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Camcevi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (150.33 KB - PDF)

**First published:** 03/04/2025

[View](/en/documents/procedural-steps-after/camcevi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Camcevi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (117.49 KB - PDF)

**First published:** 12/05/2023

**Last updated:** 03/04/2025

[View](/en/documents/procedural-steps-after/camcevi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Camcevi-H-C-PSUSA-00010877-202307 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/107562/2024

English (EN) (93.91 KB - PDF)

**First published:** 05/06/2024

[View](/en/documents/scientific-conclusion/camcevi-h-c-psusa-00010877-202307-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Camcevi : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/567396/2022

English (EN) (3.61 MB - PDF)

**First published:** 20/06/2022

[View](/en/documents/assessment-report/camcevi-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Camcevi

Adopted

Reference Number: EMA/CHMP/138725/2022

English (EN) (165.65 KB - PDF)

**First published:** 25/03/2022

[View](/en/documents/smop-initial/chmp-summary-opinion-camcevi_en.pdf)

#### News on Camcevi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 March 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-march-2022) 25/03/2022

**This page was last updated on** 03/04/2025

## Share this page

[Back to top](#main-content)